Tetrahydrocannabinol (Delta 9-THC) treatment in chronic central neuropathic pain and fibromyalgia patients: Results of a multicenter survey

Anesthesiology Research and Practice

Volumn 2009, Issue , 2009, Pages

  Konrad, Christoph ^a   Weber, Janet ^a   Schley, Marcus ^b   Casutt, Matthias ^a   Gerber, Helmut ^a   Schuepfer, Guido ^a   Rukwied, Roman ^a   Schleinzer, Wolfgang ^c   Ueberall, Michael ^d  

^a LUZERNER KANTONSSPITAL   (Switzerland)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c SWISS PARAPLEGIC RESEARCH   (Switzerland)

^d Department of Neuroscience Algesiology and Pediatrics ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BUPRENORPHINE; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DIPYRONE; DRONABINOL; FENTANYL; FLUPIRTINE; HYDROMORPHONE; MORPHINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NALOXONE; NONSTEROID ANTIINFLAMMATORY AGENT; OXYCODONE; PARACETAMOL; TRAMADOL;

ADULT; AGED; CHRONIC PAIN; CLINICAL ASSESSMENT TOOL; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FIBROMYALGIA; HOSPITAL ANXIETY DEPRESSION SCALE; HUMAN; INCREASED APPETITE; MAJOR CLINICAL STUDY; MALE; MEDICAL OUTCOMES SHORT FORM; NEUROPATHIC PAIN; PAIN ASSESSMENT; PAIN DISABILITY INDEX; PRIORITY JOURNAL; PSYCHOMETRY; QUALITY OF LIFE; QUALITY OF LIFE IMPAIRMENT BY PAIN; RETROSPECTIVE STUDY; REVIEW; SEDATION; SIDE EFFECT; TREATMENT OUTCOME;

EID: 77955381319     PISSN: 16876962     EISSN: 16876970     Source Type: Journal    
DOI: 10.1155/2009/827290     Document Type: Review

References (51)

1. Freeman R., The treatment of neuropathic pain CNS Spectrums 2005 10 9 698 706
2. Saarto T., Wiffen P. J., Antidepressants for neuropathic pain Cochrane Database of Systematic Reviews 2007 4
3. Bowsher D., Neurogenic pain syndromes and their management British Medical Bulletin 1991 47 3 644 666
4. Calignano A., La Rana G., Giuffrida A., Piomelli D., Control of pain initiation by endogenous cannabinoids Nature 1998 394 6690 277 281
5. Iversen L., Cannabis and the brain Brain 2003 126 6 1252 1270
6. Mackie K., Cannabinoid receptors as therapeutic targets Annual Review of Pharmacology and Toxicology 2006 46 101 122
7. Rukwied R., Gauter B., Schley M., Konrad C., Cannabinoidssignal transduction and mode of action Schmerz 2005 19 6 528 534
8. Sullivan J. M., Cellular and molecular mechanisms underlying learning and memory impairments produced by cannabinoids Learning and Memory 2000 7 3 132 139
9. Mechoulam R., Gaoni Y., The absolute configuration of 1-tetrahydrocannabinol, the major active constituent of hashish Tetrahedron Letters 1967 8 12 1109 1111
10. Iuvone T., Esposito G., De Filippis D., Scuderi C., Steardo L., Cannabidiol: a promising drug for neurodegenerative disorders? CNS Neuroscience and Therapeutics 2009 15 1 65 75
11. Baker D., Pryce G., The endocannabinoid system and multiple sclerosis Current Pharmaceutical Design 2008 14 23 2326 2336
12. Manzanares J., Julian M. D., Carrascosa A., Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes Current Neuropharmacology 2006 4 3 239 257
13. Baker D., Pryce G., Giovannoni G., Thompson A. J., The therapeutic potential of cannabis Lancet Neurology 2003 2 5 291 298
14. Russo E. B., Cannabinoids in the management of difficult to treat pain Therapeutics and Clinical Risk Management 2008 4 1 245 259
15. Karst M., Wippermann S., Cannabinoids against pain. Efficacy and strategies to reduce psychoactivity: a clinical perspective Expert Opinion on Investigational Drugs 2009 18 2 125 133
16. Rog D. J., Nurmikko T. J., Young C. A., Oromucosal 9 - tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial Clinical Therapeutics 2007 29 9 2068 2079
17. Zajicek J., Fox P., Sanders H., Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial The Lancet 2003 362 9395 1517 1526
18. Croxford J. L., Therapeutic potential of cannabinoids in CNS disease CNS Drugs 2003 17 3 179 202
19. Woolridge E., Barton S., Samuel J., Osorio J., Dougherty A., Holdcroft A., Cannabis use in HIV for pain and other medical symptoms Journal of Pain and Symptom Management 2005 29 4 358 367
20. Gourlay D., Addiction and pain medicine Pain Research and Management 2005 10 supplement A 38A 43A
21. Buggy D. J., Toogood L., Maric S., Sharpe P., Lambert D. G., Rowbotham D. J., Lack of analgesic efficacy of oral -9-tetrahydrocannabinol in postoperative pain Pain 2003 106 1-2 169 172
22. Clermont-Gnamien S., Atlani S., Attal N., Le Mercier F., Guirimand F., Brasseur L., The therapeutic use of D9-tetrahydrocannabinol (dronabinol) in refractory neuropathic pain Presse Medicale 2002 31 39, part 1 1840 1845
23. Naef M., Curatolo M., Petersen-Felix S., Arendt-Nielsen L., Zbinden A., Brenneisen R., The analgesic effect of oral delta-9-tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions Pain 2003 105 1-2 79 88
24. Kraft B., Frickey N. A., Kaufmann R. M., Lack of analgesia by oral standardized cannabis extract on acute inflammatory pain and hyperalgesia in volunteers Anesthesiology 2008 109 1 101 110
25. Narang S., Gibson D., Wasan A. D., Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy Journal of Pain 2008 9 3 254 264
26. Toth C., Au S., A prospective identification of neuropathic pain in specific chronic polyneuropathy syndromes and response to pharmacological therapy Pain 2008 138 3 657 666
27. Staud R., Domingo M., Evidence for abnormal pain processing in fibromyalgia syndrome Pain Medicine 2001 2 3 208 215
28. Desmeules J. A., Cedraschi C., Rapiti E., Neurophysiologic evidence for a central sensitization in patients with fibromyalgia Arthritis and Rheumatism 2003 48 5 1420 1429
29. Rowbotham M. C., Is fibromyalgia a neuropathic pain syndrome? Journal of Rheumatology 2005 32 supplement 75 38 40
30. Wolfe F., Smythe H. A., Yunus M. B., The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the multicenter criteria committee Arthritis and Rheumatism 1990 33 2 160 172
31. Katz R. S., Wolfe F., Michaud K., Fibromyalgia diagnosis: a comparison of clinical, survey, and American College of Rheumatology criteria Arthritis and Rheumatism 2006 54 1 169 176
32. Clauw D. J., Assessing and diagnosing fibromyalgia in the clinical setting The Journal of Clinical Psychiatry 2008 69 11, article e33
33. Tramr M. R., Carroll D., Campbell F. A., Reynolds D. J. M., Moore R. A., McQuay H. J., Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review British Medical Journal 2001 323 7303 16 21
34. Beal J. E., Olson R., Lefkowitz L., Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia Journal of Pain and Symptom Management 1997 14 1 7 14
35. Roberts J. D., Gennings C., Shih M., Synergistic affective analgesic interaction between delta-9- tetrahydrocannabinol and morphine European Journal of Pharmacology 2006 530 1-2 54 58
36. Iskedjian M., Bereza B., Gordon A., Piwko C., Einarson T. R., Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain Current Medical Research and Opinion 2007 23 1 17 24
37. Svendsen K. B., Jensen T. S., Bach F. W., Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial British Medical Journal 2004 329 7460 253 257
38. Wade D. T., Robson P., House H., Makela P., Aram J., A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms Clinical Rehabilitation 2003 17 1 21 29
39. Rog D. J., Nurmikko T. J., Young C. A., Oromucosal 9 - tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial Clinical Therapeutics 2007 29 9 2068 2079
40. Rog D. J., Nurmikko T. J., Friede T., Young C. A., Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis Neurology 2005 65 6 812 819
41. Seeling W., Kneer L., Bchele B., 9 -tetrahydrocannabinol and the opioid receptor agonist piritramide do not act synergistically in postoperative pain Anaesthesist 2006 55 4 391 400
42. Attal N., Brasseur L., Guirimand D., Clermond-Gnamien S., Atlami S., Bouhassira D., Are oral cannabinoids safe and effective in refractory neuropathic pain? European Journal of Pain 2004 8 2 173 177
43. Hill M. N., Gorzalka B. B., Pharmacological enhancement of cannabinoid CB1 receptor activity elicits an antidepressant-like response in the rat forced swim test European Neuropsychopharmacology 2005 15 6 593 599
44. Witkin J. M., Tzavara E. T., Nomikos G. G., A role for cannabinoid CB1 receptors in mood and anxiety disorders Behavioural Pharmacology 2005 16 5-6 315 331
45. Marsicano G., Wotjak C. T., Azad S. C., The endogenous cannabinoid system controls extinction of aversive memories Nature 2002 418 6897 530 534
46. Berman J. S., Symonds C., Birch R., Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial Pain 2004 112 3 299 306
47. Marras W. S., Ferguson S. A., Burr D., Schabo P., Maronitis A., Low back pain recurrence in occupational environments Spine 2007 32 21 2387 2397
48. Cichewicz D. L., Synergistic interactions between cannabinoid and opioid analgesics Life Sciences 2004 74 11 1317 1324
49. Vigan D., Rubino T., Parolaro D., Molecular and cellular basis of cannabinoid and opioid interactions Pharmacology Biochemistry and Behavior 2005 81 2 360 368
50. Jensen T. S., Finnerup N. B., Management of neuropathic pain Current Opinion in Supportive and Palliative Care 2007 1 2 126 131
51. Palazzo E., Marabese I., de Novellis V., Metabotropic and NMDA glutamate receptors participate in the cannabinoid-induced antinociception Neuropharmacology 2001 40 3 319 326 (Pubitemid 32144710)